Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitget launches U-based ZEST and BTW perpetual contracts, supporting up to 10x leverage

Bitget launches U-based ZEST and BTW perpetual contracts, supporting up to 10x leverage

BlockBeatsBlockBeats2026/06/05 05:51

BlockBeats News, June 5th, according to an official announcement, Bitget has now launched U-based ZEST and BTW perpetual contracts, both supporting up to 10x leverage. The contract trading bot will also be available simultaneously. For more details, please refer to the Bitget official platform.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure

According to media reports citing sources familiar with the matter, SpaceX is preparing to complete a debt issuance totaling $40 billion, with an interest rate significantly higher than previous borrowing costs, reflecting growing investor concerns over financing for artificial intelligence (AI) infrastructure.

智通财经•2026/10/23 01:02
$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure

TS Lombard scenario analysis: An AI bubble burst could trigger a 30% plunge in the S&P 500, wiping out 20 trillion dollars in market value—but don't rush to short!

Dario Perkins from TS Lombard predicted in a scenario analysis released on Thursday that if AI capital expenditure collapses, approximately $20 trillions in U.S. stock market value could evaporate, triggering credit losses of $125 billions to $190 billions.

智通财经•2026/10/23 00:56

Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline

Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.

智通财经•2026/10/23 00:37